Takeda Pharmaceutical rated Hold amid weak cash flow and slow new drug growth despite improved margins.

Takeda Pharmaceutical maintains a Hold rating due to concerns over its ability to replace major drug revenues and current valuation. Although operating margin improved to 17% thanks to lower amortization, operating cash flow dropped to $2.74 billion, indicating weak underlying cash generation. New drugs Mimrylo and Orzeyful have been slow to gain traction and contribute little, while Entyvio remains the main revenue source. Trading at a 21x forward P/E with a 3.15% yield, Takeda lacks strong growth or value catalysts, making its current stock price unattractive for investors.

As of Oct 30, 2026 18:42 WIB, Takeda Pharmaceutical's American Depositary Shares trade at USD 21.00 on Pluang, showing a 4.95% increase for the day. The stock carries a dividend yield of 3.08% and a market capitalization of $65.49 billion. Despite the earnings growth challenges noted in the article, Takeda's shares are experiencing notable daily gains on the platform.